• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Current Status of Sorafenib Use for Treatment of Hepatocellular Carcinoma.

作者信息

El-Serag Hashem B, Margaret M, Alkek Albert B

机构信息

Professor and Chair Department of Medicine Baylor College of Medicine Houston, Texas.

出版信息

Gastroenterol Hepatol (N Y). 2017 Oct;13(10):623-625.

PMID:29230141
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5718181/
Abstract
摘要

相似文献

1
Current Status of Sorafenib Use for Treatment of Hepatocellular Carcinoma.索拉非尼用于治疗肝细胞癌的现状
Gastroenterol Hepatol (N Y). 2017 Oct;13(10):623-625.
2
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial.乐伐替尼对比索拉非尼用于不可切除肝细胞癌的一线治疗：来自一项随机、开放标签、非劣效、III 期临床试验的患者报告结局。
Lancet Gastroenterol Hepatol. 2021 Aug;6(8):649-658. doi: 10.1016/S2468-1253(21)00110-2. Epub 2021 Jun 2.
3
Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.动脉内注射TheraSphere钇-90玻璃微球治疗不可切除肝细胞癌患者：STOP-HCC 3期随机对照试验方案
JMIR Res Protoc. 2018 Aug 15;7(8):e11234. doi: 10.2196/11234.
4
Systemic therapy for hepatocellular carcinoma: current status and future perspectives.肝细胞癌的系统治疗：现状与未来展望
Jpn J Clin Oncol. 2021 Aug 30;51(9):1363-1371. doi: 10.1093/jjco/hyab108.
5
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.钇[90Y]树脂微球选择性内放射治疗与索拉非尼治疗局部进展期不可切除肝细胞癌的疗效和安全性比较（SARAH）：一项开放标签随机对照 3 期临床试验。
Lancet Oncol. 2017 Dec;18(12):1624-1636. doi: 10.1016/S1470-2045(17)30683-6. Epub 2017 Oct 26.
6
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.信迪利单抗联合贝伐珠单抗生物类似药（IBI305）对比索拉非尼治疗不可切除肝细胞癌（ORIENT-32）：一项随机、开放标签的2/3期研究
Lancet Oncol. 2021 Jul;22(7):977-990. doi: 10.1016/S1470-2045(21)00252-7. Epub 2021 Jun 15.
7
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.纳武利尤单抗对比索拉非尼用于治疗晚期肝细胞癌（CheckMate 459）：一项随机、多中心、开放标签、III 期临床试验。
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13.
8
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.索拉非尼在亚太地区晚期肝细胞癌患者中的疗效和安全性：一项III期随机、双盲、安慰剂对照试验。
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
9
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.阿替利珠单抗联合贝伐珠单抗与索拉非尼治疗不可切除肝细胞癌患者的患者报告结局（IMbrave150）：一项开放标签、随机、3期试验
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
10
Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma.索拉非尼纳米颗粒递送系统在肝细胞癌治疗中的现状
Theranostics. 2021 Mar 13;11(11):5464-5490. doi: 10.7150/thno.54822. eCollection 2021.

引用本文的文献

1
Investigation of magnesium aluminometasilicate (Neusilin US2) based surface solid dispersion of sorafenib tosylate using QbD approach: and pharmacokinetic study.采用质量源于设计（QbD）方法对基于硅酸铝镁（Neusilin US2）的甲苯磺酸索拉非尼表面固体分散体进行研究及药代动力学研究。
ADMET DMPK. 2024 Aug 9;12(4):687-702. doi: 10.5599/admet.2338. eCollection 2024.
2
Optimization of 3D-aggregated spheroid model (3D-ASM) for selecting high efficacy drugs.用于筛选高效药物的 3D 聚集球体模型（3D-ASM）的优化。
Sci Rep. 2022 Nov 7;12(1):18937. doi: 10.1038/s41598-022-23474-5.
3
Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.二甲双胍通过抑制 MAPK/ERK/Stat3 轴增强索拉非尼在肝癌中的抗癌疗效。
Int J Mol Sci. 2022 Jul 22;23(15):8083. doi: 10.3390/ijms23158083.
4
Impact of tenofovir antiviral treatment on survival of chronic hepatitis B related hepatocellular carcinoma after hepatectomy in Chinese individuals from Qingdao municipality.替诺福韦抗病毒治疗对青岛市中国慢性乙型肝炎相关肝细胞癌患者肝切除术后生存的影响
Medicine (Baltimore). 2020 Aug 7;99(32):e21454. doi: 10.1097/MD.0000000000021454.
5
AAV3-miRNA vectors for growth suppression of human hepatocellular carcinoma cells in vitro and human liver tumors in a murine xenograft model in vivo.腺相关病毒 3 微小 RNA 载体对人肝癌细胞的体外生长抑制作用及其在小鼠异种移植模型中的体内人肝癌肿瘤抑制作用。
Gene Ther. 2021 Aug;28(7-8):422-434. doi: 10.1038/s41434-020-0140-1. Epub 2020 Mar 9.
6
Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study.索拉非尼对接受经动脉化疗栓塞术的中期肝细胞癌患者的疗效及安全性：一项回顾性对照研究。
World J Clin Cases. 2018 May 16;6(5):74-83. doi: 10.12998/wjcc.v6.i5.74.

本文引用的文献

1
Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: A systematic review and meta-analysis.伴有大血管侵犯或转移的晚期肝细胞癌的治疗方法：系统评价和荟萃分析。
Hepatology. 2018 Jan;67(1):422-435. doi: 10.1002/hep.29486.
2
AASLD guidelines for the treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌治疗指南。
Hepatology. 2018 Jan;67(1):358-380. doi: 10.1002/hep.29086.
3
Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.索拉非尼治疗晚期肝细胞癌的生存和成本效益：SEER-医疗保险数据库分析。
Hepatology. 2017 Jan;65(1):122-133. doi: 10.1002/hep.28881. Epub 2016 Nov 25.
4
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.在 Child-Pugh 亚组中观察索拉非尼在临床实践中的应用：GIDEON 研究。
J Hepatol. 2016 Dec;65(6):1140-1147. doi: 10.1016/j.jhep.2016.07.020. Epub 2016 Jul 25.
5
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.TACE 治疗索拉非尼治疗失败的不可切除肝细胞癌患者的临床实践：GIDEON 的最终分析。
Radiology. 2016 May;279(2):630-40. doi: 10.1148/radiol.2015150667. Epub 2016 Jan 8.
6
EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.欧洲肝脏研究学会-欧洲肿瘤内科学会临床实践指南：肝细胞癌的管理
J Hepatol. 2012 Apr;56(4):908-43. doi: 10.1016/j.jhep.2011.12.001.
7
Management of hepatocellular carcinoma: an update.肝细胞癌的管理：最新进展
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
8
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.索拉非尼在亚太地区晚期肝细胞癌患者中的疗效和安全性：一项III期随机、双盲、安慰剂对照试验。
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
9
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.